Psychopharmacology

, Volume 99, Issue 1, pp 87–90 | Cite as

The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward

  • L. J. Herberg
  • I. C. Rose
Original Investigations
Received:
Accepted:

Abstract

MK-801 is a ligand at phencyclidine recognition sites associated with NMDA-coupled cation channels, where it acts as a potent noncompetitive antagonist of central glutamate/aspartate (NMDA-type) receptors. Low doses (10–100 μg/kg IP) produced a dose-related and prolonged (>1 h) enhancement of variable-interval self-stimulation responding. Higher doses (300 μg/kg) caused flaccid ataxia and disrupted responding. Ketamine HCl (3.0–100 mg/kg IP), a dissociative anaesthetic binding to the phencyclidine site, produced a similar response pattern, but facilitation was less prolonged and occurred over a narrower dose range. Kynurenic acid (3.0–300 mg/kg IP), a nonselective competitive antagonist of glutamate receptors, produced only depression of responding, possibly the result of kynurenate-induced blockade of central kainate and/or quisqualate receptors. The behavioural stimulant effects of MK-801 appear to be an intrinsic and essential feature of selective NMDA antagonists, and these effects of MK-801 differ qualitatively and quantitatively from the well-known facilitatory effects of dopamine-dependent stimulants.

Key words

Glutamate Kainate Ketamine Kynurenic acid MK-801 NMDA Phencyclidine Rat Self-stimulation 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anis MA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565–575Google Scholar
  2. de Belleroche JS, Rose FC (1987) Zinc, glutamate receptors, and motoneurone disease. Lancet II:1082–1083Google Scholar
  3. de Belleroche JS, Recordati A, Rose FC (1984) Elevated levels of amino acids in the CSF of motor neurone disease patients. Neurochem Pathol 2:1–6Google Scholar
  4. Benvenga MJ, Spaulding TC (1988) Amnesic effect of the novel anticonvulsant MK-801. Pharmacol Biochem Behav 30:205–207Google Scholar
  5. Boldry RC, Uretsky NJ (1988) The importance of dopaminergic neurotransmission in the hypermotility response produced by administration ofN-methyl-d-aspartic acid into the nucleus accumbens. Neuropharmacology 27:569–577Google Scholar
  6. Bridges RJ, Geddes JW, Monaghan DT, Cotman CW (1988) Excitatory amino acid receptors in Alzheimer's disease. In: Lodge D (ed) Excitatory amino acids in health and disease. Wiley, New York, pp 321–335Google Scholar
  7. Clineschmidt BV, Martin GE, Bunting PR (1982a) Anticonvulsant activity of (±)-5-methyl-10,11-dihydro-5H-dibenzo-[a, d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:123–134Google Scholar
  8. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982b) Central sympathomimetic activity of (±)-5-methyl-10,11-dihydro-5H-dibenzo-[a, d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:134–145Google Scholar
  9. Clineschmidt BV, Williams M, Witoslawsky JJ, Bunting PR, Risley EA, Totaro JA (1982c) Restoration of shock-suppressed behavior by treatment with (±)-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:147–163Google Scholar
  10. Danysz W, Wroblewski JT, Costa E (1988) Learning impairment in rats byN-methyl-d-aspartate receptor antagonists. Neuropharmacology 27:653–656Google Scholar
  11. Davies J, Stanley MDA (1988) Specificity of excitatory amino acid agonists and antagonists. In: Lodge D (ed) Excitatory amino acids in health and disease. Wiley, Chichester, pp 47–62Google Scholar
  12. Domino EF (1978) Some aspects of the pharmacology of phencyclidine. In: Stillman RC, Wilette RE (eds) The psychopharmacology of hallucinogens. Pergamon Press, New York, pp 105–117Google Scholar
  13. Engelsen B (1986) Neurotransmitter glutamate: its clinical importance. Acta Neurol Scand 74:337–355Google Scholar
  14. Foster AC, Gill R, Kemp JA, Woodruff GN (1987) Systemic administration of MK-801 preventsN-methyl-d-aspartate-induced neuronal degeneration in rat brain. Neurosci Lett 76:307–311Google Scholar
  15. Ganong AH, Lanthorn TH, Cotman CW (1983) Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Res 273:170–174Google Scholar
  16. Gardner EL, Paredes W, Smith D, Donner C, Milling D, Cohen D, Morrison D (1988) Facilitation of brain stimulation reward by Δ9-tetrahydrocannabinol. Psychopharmacology 96:142–144Google Scholar
  17. Hamilton MH, de Belleroche JS, Gardiner IM, Herberg LJ (1986) Stimulatory effect of N-methyl aspartate on locomotor activity and transmitter release from rat nucleus accumbens. Pharmacol Biochem Behav 25:943–948Google Scholar
  18. Herberg LJ, Rose IC (1988) Do excitatory amino-acid pathways mediate brain-stimulation reward? Psychopharmacology 96:S25Google Scholar
  19. Herberg LJ, Williams SF (1983) Anti-conflict and depressant effects by GABA agonists and antagonists, benzodiazepines and non-gabergic anticonvulsants on self-stimulation and locomotor activity. Pharmacol Biochem Behav 19:625–633Google Scholar
  20. Herberg LJ, Stephens DN, Franklin KBJ (1976) Catecholamines and self-stimulation: evidence suggesting a reinforcing role for noradrenaline and a motivating role for dopamine. Pharmacol Biochem Behav 4:575–582Google Scholar
  21. Hucker HB, Hutt JE, White SD, Arison BH, Zacchei AG (1983) Disposition and metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5,10-imine in rats, dogs and monkeys. Drug Metab Dispos 11:54–58Google Scholar
  22. Kleinschmidt A, Bear MF, Singer W (1987) Blockade of “NMDA” receptors disrupts experience-dependent plasticity of kitten striate cortex. Science 238:355–358Google Scholar
  23. Leung LY, Baillie TA (1986) Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 29:2396–2399Google Scholar
  24. Liebman JM (1983) Discriminating between reward and performance: a critical review of intracranial self-stimulation methodology. Neurosci Biobehav Rev 7:45–72Google Scholar
  25. Liebman JM, Amrick CL, Bernard PS, Pastor G, Boast CA, Bennett DA (1987) Distinctive behaviours induced in rodents by high doses of 2-amino-7-phosphonoheptanoic acid. In: Hicks TP, Lodge D, McLennan J (eds) Excitatory amino acid transmission. Liss, New York, pp 261–264Google Scholar
  26. Lodge D, Aram JA, Church J, Davies SN, Martin D, Millar J, Zeman S (1988) Sigma opiates and excitatory amino acids. In: Lodge D (ed) Excitatory amino acids in health and disease. Wiley, New York, pp 237–259Google Scholar
  27. Loo PA, Braunwalder AF, Williams M, Sills MA (1987) The novel anticonvulsant MK-801 interacts with central phencyclidine recognition sites in rat brain. Eur J Pharmacol 135:261–263Google Scholar
  28. McCabe BJ, Horn G (1988) Learning and memory: regional changes inN-methyl-d-aspartate receptors in the chick brain after imprinting. Proc Nalt Acad Sci USA 85:2849–2853Google Scholar
  29. McNamara JO, Russel RD, Rigsbee L, Bonhaus DW (1988) Anticonvulsant and antiepileptogenic actions of MK-801 in kindling and lectroshock models. Neuropharmacology 27:653–568Google Scholar
  30. Maragos WF, Greenamyre T, Penney JB Jr, Young AB (1987) Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci 10:65–68Google Scholar
  31. Martin GE (1986) Catecholamine release within the striatum of the freely moving rat. Ann NY Acad Sci 473:151–159Google Scholar
  32. Morris RGM, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by anN-methyl-d-aspartate receptor antagonist, AP5. Nature 319:774–776Google Scholar
  33. Olney JW (1987) Excitatory amino acids and neuropsychiatric disorders. In: Hicks TP, Lodge D (eds) Excitatory amino acid transmission. Liss, New York, pp 217–224Google Scholar
  34. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain. Plenum Press, New YorkGoogle Scholar
  35. Reid LD, Gibson WE, Gledhill SM, Porter PB (1964) Anticonvulsant drugs and self-stimulating behaviour. J Comp Physiol Psychol 57:353–356Google Scholar
  36. Rose IC, Mintz M, Herberg LJ (1988) Chronicl-dopa fails to lessen rebound enhancement of self-stimulation after chronic haloperidol. Pharmacol Biochem Behav 30:585–588Google Scholar
  37. Schwarcz R, Meldrum B (1985) Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders. Lancet II:140–143Google Scholar
  38. Stone TW, Connick JH (1985) Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15:597–617Google Scholar
  39. Wise RA (1982) Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 5:39–87Google Scholar
  40. Wise RA, Bozarth MA (1982) Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav 17:239–243Google Scholar
  41. Wong EHF, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potentN-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 83:7104–7108Google Scholar
  42. Woodruff GN, Foster AC, Wong EHF, Gill R, Kemp JA, Iversen LL (1988) Excitatory amino acids and neurodegenerative disorders: possible therapeutic indications. In: Lodge D (ed) Excitatory amino acids in health and disease. Wiley, New York, pp 379–389Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • L. J. Herberg
    • 1
  • I. C. Rose
    • 1
  1. 1.Experimental Psychology LaboratoryInstitute of NeurologyLondonUK

Personalised recommendations